Drugs company questions patent pool concept
A lawyer for one of the world’s biggest pharmaceutical companies has said that pooling patents over drugs will not solve the major problems of access to medicines
Speaking at the Competition 2009 conference in Brussels on
Friday, Stéphane Drouin, head of European patents at
Pfizer, said that IP is not a major issue when it comes to
accessing drugs in least developed countries.
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of one week’s FREE access
and become a Managing IP member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain 7 days FREE access when you register now.